Developer docs
API playgroundTry for free, no card

Search company profiles

Keensight Capital

Full company profile

uuid0000354

Namestring
Keensight Capital
Legal namestring
Keensight Capital (société par actions simplifiée)
Websiteurl
keensight.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Keensight Capital is a European Growth Buyout private equity firm specialising exclusively in profitable, fast-growing mid-market Technology and Healthcare companies. Headquartered in Paris and regulated by the Autorité des Marchés Financiers (agreement GP-08000040), the firm deploys €10-800m tickets in minority or majority positions, with or without leverage, into companies generating €10-400m in revenues. Keensight invests across Europe with additional operating presence in London, Boston and Singapore, and reports reach across more than 90 countries. The firm originated as R Capital Management, the growth-investment arm of the Rothschild Group, before becoming independent under its Managing Partners.

Keensight operates two proprietary assets that distinguish it from a capital-only sponsor. Keensight Connect is an online collaborative platform that connects Founders, CEOs and senior executives of portfolio companies through functional communities (Finance, HR, Sales, Product, Marketing) for knowledge sharing and access to curated documentation. Keensight Performance is an in-house operating team of approximately 40 professionals providing embedded functional expertise across product, technology, marketing, AI, sales, capital markets and M&A throughout the investment lifecycle. As of December 31, 2025 the firm reports €8bn+ in assets under management, 88 cumulative investments, 51 exits, 39% IRR from exited investments, and 18% average annual portfolio revenue growth over the past five years.

Keensight generates revenue through private equity fund management fees on assets under management and carried interest on successful exits. Capital is sourced from institutional Limited Partners via its Investor Relations team and deployed via direct deal-sourcing relationships with founders, management teams and selling shareholders. The firm is independent and partner-owned (simplified joint-stock company, RCS Paris 509 104 527), led by Founding Partner Jean-Michel BEGHIN with senior leadership spanning Partner/COO Arnaud COHEN, CFO Adrien VAN EYNDE, Global Head of Investor Relations Charles COX, Head of ESG & Sustainability Ana ALVAREZ GRULLON and Head of Keensight Performance Stephane Prats. The current portfolio spans vertical software (Decision Focus, Aconso, SoftCo, Onventis, Quanos, Dimo Maint, ACTICO), IT services (Plat4mation, Valiantys, Nomios, Inherent), and Healthcare (Symeres, Inke, Bedfont Scientific, Isto Biologics, 3PBIOVIAN, Bentley, Unither, AXXAM, CatSci).

Short descriptiontext

Keensight Capital is a European Growth Buyout private equity firm investing exclusively in profitable mid-market Technology and Healthcare companies via €10-800m tickets, supported by an in-house operating team and a proprietary portfolio community platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity investing, growth buyout investments, technology equity investing, healthcare equity investing, portfolio value creation
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Private Equity / Growth Buyout Investing
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Private equity fund management fees & carried interest
TypeManaged Services
Description

Keensight Capital earns revenue by managing private equity funds and investing in profitable European Technology and Healthcare companies. Revenue is generated through management fees on assets under management and carried interest on successful exits. Keensight operates across more than 90 countries with €8bn+ AUM as of December 31, 2025.

keensight.com
2Fund capital deployment gains
TypeSubscription Recurring
Description

Capital is invested via Growth Buyout structures (minority or majority, with or without leverage) in profitable companies generating €10-400m in revenues. Keensight reports a 39% IRR from 51 exited investments and 18% average annual portfolio revenue growth over the past 5 years, driving fund returns.

keensight.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Investment ticket size range: €10m–€800m for portfolio companies generating €10m–€400m in revenues
ModelOtherBilling cadenceMulti-year contract
Notes

Not publicly disclosed; tailored to individual transactions as minority or majority partner, with or without leverage.

keensight.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Keensight Connect
Description

Online collaborative platform for Founders, CEOs and managers of Keensight's portfolio companies, designed as a community of communities for knowledge sharing across the portfolio.

keensight.com
+1 more record
Core offering1 text field

Keensight Capital is a European Growth Buyout investor that deploys €10–800m tickets in minority or majority positions into profitable, fast-growing European Technology and Healthcare companies generating €10–400m in revenues. The firm provides capital alongside strategic guidance and operational support delivered through its proprietary Keensight Performance team of ~40 in-house professionals, while Keensight Connect serves as the online community platform for portfolio company executives.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 39% IRR from a total of 51 exited investments
+6 more records
Product overview1 text field

Keensight Capital is a European Growth Buyout investor (private equity firm) whose direct product offering is built around two proprietary assets: (1) Keensight Connect, an online collaborative platform serving as a community of communities for CEOs, founders and senior executives across Keensight's portfolio companies with curated best-practice documentation and live groups across Finance, HR, Sales, Product, and Marketing; and (2) Keensight Performance, an in-house operational support team of ~40 professionals providing on-demand expertise across product, technology, marketing, AI, sales, capital markets, M&A and revenue generation. Beyond these internal platforms, Keensight's broader commercial offering is its pan-European Growth Buyout investment service — providing €10–800m tickets in minority or majority positions to profitable Technology and Healthcare companies generating €10m–€400m in revenues. The investment vehicle is delivered through a portfolio of named operating companies, each with its own product: in Technology this includes Bedfont Scientific (non-invasive breath analysis medical devices), Decision Focus (no-code GRC SaaS with AI-powered capabilities), Isto Biologics (orthobiologics/regenerative MedTech), UVE (Route-to-Market analytics SaaS for CPG brands), Dimo Maint (CMMS SaaS), aconso (AI-powered HR document management), SoftCo (Procure-to-Pay SaaS), Plat4mation (ServiceNow Elite Partner services), MetaCompliance (Human Risk Management platform), Advancis (Physical Security Information Management), Nomios (cybersecurity services), ACTICO (regulatory compliance/risk management SaaS), Inherent (B2B cloud and connectivity services), Valiantys (Atlassian services), Onventis (cloud procurement), Sogelink (civil engineering digitalization), and Quanos (industrial aftersales documentation); in Healthcare, Symeres (drug discovery CRO/CDMO) and Inke (inhalation API manufacturing).

Product and service3 records
1European Growth Buyout investment platform
CategoryInvestment service
Description

Core investment offering providing €10–800m investment tickets in minority or majority positions, with or without leverage, to fast-growing and profitable European Technology and Healthcare companies generating €10m to €400m in revenues. Includes tailor-made financing for organic growth, strategic acquisitions, or shareholder liquidity.

2Keensight Connect
CategoryOnline collaborative platform
Description

Online collaborative platform for Founders, CEOs and senior executives of Keensight's portfolio companies. It operates as a community of communities, connecting portfolio managers across multiple live groups (Finance, HR, Sales, Product, Marketing) and providing curated documentation and best-practice resources to support value creation.

3Keensight Performance
CategoryIn-house operational support team
Description

In-house team of approximately 40 professionals providing on-demand operational support to portfolio companies, with in-house expertise across product, technology, marketing, AI, sales, capital markets, M&A, and revenue generation functions. Works alongside investment teams from the pre-deal phase through the investment lifecycle.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

ServiceNow Ecosystem Ventures co-invests with Keensight Capital in Plat4mation to support the ServiceNow Elite Partner's international expansion. The recent Adeno acquisition (June 2026) is supported by both Keensight Capital and ServiceNow Ecosystem Ventures.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-12-03
Description

Cuatrecasas advised UVE Solutions on the sale of a majority stake to Keensight Capital (December 2025). Keensight aims to accelerate UVE's international expansion and support new artificial intelligence investments.

3investorsinhealthcare (publisher reference)
Strategic tierMinorTypeOthersAnnounced on2025-10-13
Description

News coverage of Keensight's majority stake acquisition in Bedfont Scientific.

investorsinhealthcare.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Advancis Software & Services GmbH, a German provider of integrated physical security software, entered into a strategic partnership with French private equity firm Keensight Capital to accelerate its international growth and PSIM solution development (November 2024).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-28
Description

Buckaroo (Keensight's portfolio company) became the exclusive strategic partner of ABN AMRO for payment services in February 2024. This partnership leverages Keensight's portfolio to provide exclusive payment services to ABN AMRO.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-14
Description

Keensight Capital and CVC Capital Partners agreed to jointly lead Sogelink through its next phase of growth in November 2023. CVC also co-invested alongside Keensight in subsequent Sogelink acquisitions including Netisys (October 2024).

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-06-29
Description

Paul Hastings advised Keensight Capital on its LBO acquisition of Valiantys (2022) and on Keensight's acquisition of a majority stake in Bedfont Scientific, a UK-based medical device company specializing in non-invasive breath analysis technology (October 2025). Repeated legal advisor relationship.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2022-04-27
Description

William Blair acted as the exclusive financial advisor to Valiantys in its pending sale to Keensight Capital (signed April 8, 2022).

Recent move15 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Ardian
TypeDirect peer
Description

Large European private investment house with growth, buyout and secondaries strategies; comparable scale (€160bn+ AUM) and pan-European origination model make it a direct comparable for Keensight's growth buyout franchise.

TypeDirect peer
Description

Paris-headquartered listed private equity firm with European mid-market buyout activities; same French origin, similar mid-large ticket sizes and European focus make it the closest domestic peer to Keensight.

TypeDirect peer
Description

Paris-based alternative asset manager with private equity, private debt, real estate and capital markets strategies; comparable French origin, pan-European footprint and growth/buyout orientation.

TypeDirect peer
Description

European mid-market private equity firm focused on profitable growth companies; similar ticket size range, pan-European deal sourcing and growth-buyout model make Bridgepoint a direct comparable.

TypeDirect peer
Description

Paris-based European private equity firm with growth-buyout focus across multiple sectors; comparable ticket sizes, French/European headquarters and mid-market growth orientation align closely with Keensight's positioning.

TypeBroad incumbent
Description

Global private equity firm and existing Keensight co-investor (Sogelink); larger AUM and broader sector mandate make it an incumbent comparable rather than a direct peer, but the partnership dynamic is material to Keensight's deal flow.

TypeBroad incumbent
Description

Global private equity firm with strong European technology and healthcare franchises (EQT Growth, EQT Healthcare); much larger scale and broader strategy, but directly comparable in sector focus and European mid-large growth-buyout activity.

TypeBroad incumbent
Description

European-headquartered global private equity firm executing mid-to-large buyouts; overlapping European deal flow and growth-buyout orientation, though at a larger average ticket size than Keensight.

TypeDirect peer
Description

London-based private equity firm exclusively focused on European software and technology-enabled services; similar sector specialization, mid-market ticket sizes and value-creation orientation make Hg the closest pure-technology comparable to Keensight's tech portfolio.

TypeDirect peer
Description

Paris-headquartered European private equity firm focused on mid-market buyouts in technology, healthcare and business services; closely comparable in French origin, sector focus and growth-buyout approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers32 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles22 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries34 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A28 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment31 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Keensight Capital

Private Equity / Growth Buyout Investingkeensight.com

Keensight Capital is a European Growth Buyout private equity firm investing exclusively in profitable mid-market Technology and Healthcare companies via €10-800m tickets, supported by an in-house operating team and a proprietary portfolio community platform.

What Keensight Capital does

Keensight Capital is a European Growth Buyout private equity firm specialising exclusively in profitable, fast-growing mid-market Technology and Healthcare companies. Headquartered in Paris and regulated by the Autorité des Marchés Financiers (agreement GP-08000040), the firm deploys €10-800m tickets in minority or majority positions, with or without leverage, into companies generating €10-400m in revenues. Keensight invests across Europe with additional operating presence in London, Boston and Singapore, and reports reach across more than 90 countries. The firm originated as R Capital Management, the growth-investment arm of the Rothschild Group, before becoming independent under its Managing Partners.

Keensight operates two proprietary assets that distinguish it from a capital-only sponsor. Keensight Connect is an online collaborative platform that connects Founders, CEOs and senior executives of portfolio companies through functional communities (Finance, HR, Sales, Product, Marketing) for knowledge sharing and access to curated documentation. Keensight Performance is an in-house operating team of approximately 40 professionals providing embedded functional expertise across product, technology, marketing, AI, sales, capital markets and M&A throughout the investment lifecycle. As of December 31, 2025 the firm reports €8bn+ in assets under management, 88 cumulative investments, 51 exits, 39% IRR from exited investments, and 18% average annual portfolio revenue growth over the past five years.

Keensight generates revenue through private equity fund management fees on assets under management and carried interest on successful exits. Capital is sourced from institutional Limited Partners via its Investor Relations team and deployed via direct deal-sourcing relationships with founders, management teams and selling shareholders. The firm is independent and partner-owned (simplified joint-stock company, RCS Paris 509 104 527), led by Founding Partner Jean-Michel BEGHIN with senior leadership spanning Partner/COO Arnaud COHEN, CFO Adrien VAN EYNDE, Global Head of Investor Relations Charles COX, Head of ESG & Sustainability Ana ALVAREZ GRULLON and Head of Keensight Performance Stephane Prats. The current portfolio spans vertical software (Decision Focus, Aconso, SoftCo, Onventis, Quanos, Dimo Maint, ACTICO), IT services (Plat4mation, Valiantys, Nomios, Inherent), and Healthcare (Symeres, Inke, Bedfont Scientific, Isto Biologics, 3PBIOVIAN, Bentley, Unither, AXXAM, CatSci).

Keensight Capital firmographics

Firmographics
Name
Keensight Capital
Legal name
Keensight Capital (société par actions simplifiée)
Website
https://keensight.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
101–250 employees
Short description
Keensight Capital is a European Growth Buyout private equity firm investing exclusively in profitable mid-market Technology and Healthcare companies via €10-800m tickets, supported by an in-house operating team and a proprietary portfolio community platform.
Ownership category
akta.pro rank

Keensight Capital industry classification

Industry
Product category
Private Equity / Growth Buyout Investing
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Private equity investing
  • Growth buyout investments
  • Technology equity investing
  • Healthcare equity investing
  • Portfolio value creation

Where Keensight Capital is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Keensight Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Private equity fund management fees & carried interest: Keensight Capital earns revenue by managing private equity funds and investing in profitable European Technology and Healthcare companies. Revenue is generated through management fees on assets under management and carried interest on successful exits. Keensight operates across more than 90 countries with €8bn+ AUM as of December 31, 2025.
  2. Fund capital deployment gains: Capital is invested via Growth Buyout structures (minority or majority, with or without leverage) in profitable companies generating €10-400m in revenues. Keensight reports a 39% IRR from 51 exited investments and 18% average annual portfolio revenue growth over the past 5 years, driving fund returns.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractInvestment ticket size range: €10m–€800m for portfolio companies generating €10m–€400m in revenues

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Keensight Capital product offering

Product offering

Core offering

Keensight Capital is a European Growth Buyout investor that deploys €10–800m tickets in minority or majority positions into profitable, fast-growing European Technology and Healthcare companies generating €10–400m in revenues. The firm provides capital alongside strategic guidance and operational support delivered through its proprietary Keensight Performance team of ~40 in-house professionals, while Keensight Connect serves as the online community platform for portfolio company executives.

Product overview

Keensight Capital is a European Growth Buyout investor (private equity firm) whose direct product offering is built around two proprietary assets: (1) Keensight Connect, an online collaborative platform serving as a community of communities for CEOs, founders and senior executives across Keensight's portfolio companies with curated best-practice documentation and live groups across Finance, HR, Sales, Product, and Marketing; and (2) Keensight Performance, an in-house operational support team of ~40 professionals providing on-demand expertise across product, technology, marketing, AI, sales, capital markets, M&A and revenue generation. Beyond these internal platforms, Keensight's broader commercial offering is its pan-European Growth Buyout investment service — providing €10–800m tickets in minority or majority positions to profitable Technology and Healthcare companies generating €10m–€400m in revenues. The investment vehicle is delivered through a portfolio of named operating companies, each with its own product: in Technology this includes Bedfont Scientific (non-invasive breath analysis medical devices), Decision Focus (no-code GRC SaaS with AI-powered capabilities), Isto Biologics (orthobiologics/regenerative MedTech), UVE (Route-to-Market analytics SaaS for CPG brands), Dimo Maint (CMMS SaaS), aconso (AI-powered HR document management), SoftCo (Procure-to-Pay SaaS), Plat4mation (ServiceNow Elite Partner services), MetaCompliance (Human Risk Management platform), Advancis (Physical Security Information Management), Nomios (cybersecurity services), ACTICO (regulatory compliance/risk management SaaS), Inherent (B2B cloud and connectivity services), Valiantys (Atlassian services), Onventis (cloud procurement), Sogelink (civil engineering digitalization), and Quanos (industrial aftersales documentation); in Healthcare, Symeres (drug discovery CRO/CDMO) and Inke (inhalation API manufacturing).

Differentiator

Problem solved

Functional benefit

Brands

  • Keensight Connect: Online collaborative platform for Founders, CEOs and managers of Keensight's portfolio companies, designed as a community of communities for knowledge sharing across the portfolio.
  • Keensight Performance

Products and services

  • European Growth Buyout investment platform Core investment offering providing €10–800m investment tickets in minority or majority positions, with or without leverage, to fast-growing and profitable European Technology and Healthcare companies generating €10m to €400m in revenues. Includes tailor-made financing for organic growth, strategic acquisitions, or shareholder liquidity.
  • Keensight Connect Online collaborative platform for Founders, CEOs and senior executives of Keensight's portfolio companies. It operates as a community of communities, connecting portfolio managers across multiple live groups (Finance, HR, Sales, Product, Marketing) and providing curated documentation and best-practice resources to support value creation.
  • Keensight Performance In-house team of approximately 40 professionals providing on-demand operational support to portfolio companies, with in-house expertise across product, technology, marketing, AI, sales, capital markets, M&A, and revenue generation functions. Works alongside investment teams from the pre-deal phase through the investment lifecycle.

Quantifiable outcome

  • 39% IRR from a total of 51 exited investments
  • +6 more outcomes

Companies that use Keensight Capital

Customer profile

Named customers32 records

Segments5 records

Ideal customer profiles3 records

Keensight Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature2 records

Keensight Capital partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • ServiceNow Ecosystem VenturescoreStrategic or Co-development Partner · 2 June 2026ServiceNow Ecosystem Ventures co-invests with Keensight Capital in Plat4mation to support the ServiceNow Elite Partner's international expansion. The recent Adeno acquisition (June 2026) is supported by both Keensight Capital and ServiceNow Ecosystem Ventures.
  • CuatrecasasminorImplementation/ SI/ Consulting Partner · 3 December 2025Cuatrecasas advised UVE Solutions on the sale of a majority stake to Keensight Capital (December 2025). Keensight aims to accelerate UVE's international expansion and support new artificial intelligence investments.
  • investorsinhealthcare (publisher reference)minorOthers · 13 October 2025News coverage of Keensight's majority stake acquisition in Bedfont Scientific.
  • Advancis Software & Services GmbHcoreStrategic or Co-development Partner · 1 November 2024Advancis Software & Services GmbH, a German provider of integrated physical security software, entered into a strategic partnership with French private equity firm Keensight Capital to accelerate its international growth and PSIM solution development (November 2024).
  • ABN AMROcoreStrategic or Co-development Partner · 28 February 2024Buckaroo (Keensight's portfolio company) became the exclusive strategic partner of ABN AMRO for payment services in February 2024. This partnership leverages Keensight's portfolio to provide exclusive payment services to ABN AMRO.
  • CVC Capital PartnerscoreStrategic or Co-development Partner · 14 November 2023Keensight Capital and CVC Capital Partners agreed to jointly lead Sogelink through its next phase of growth in November 2023. CVC also co-invested alongside Keensight in subsequent Sogelink acquisitions including Netisys (October 2024).
  • Paul Hastings (Europe) LLPminorImplementation/ SI/ Consulting Partner · 29 June 2022Paul Hastings advised Keensight Capital on its LBO acquisition of Valiantys (2022) and on Keensight's acquisition of a majority stake in Bedfont Scientific, a UK-based medical device company specializing in non-invasive breath analysis technology (October 2025). Repeated legal advisor relationship.
  • William BlairminorImplementation/ SI/ Consulting Partner · 27 April 2022William Blair acted as the exclusive financial advisor to Valiantys in its pending sale to Keensight Capital (signed April 8, 2022).

Scale indicators13 records

Recent moves15 records

Expansion highlights6 records

Keensight Capital competitors and assessment

Company assessment

Direct peers

  • Ardian: Large European private investment house with growth, buyout and secondaries strategies; comparable scale (€160bn+ AUM) and pan-European origination model make it a direct comparable for Keensight's growth buyout franchise.
  • Eurazeo: Paris-headquartered listed private equity firm with European mid-market buyout activities; same French origin, similar mid-large ticket sizes and European focus make it the closest domestic peer to Keensight.
  • Tikehau Capital: Paris-based alternative asset manager with private equity, private debt, real estate and capital markets strategies; comparable French origin, pan-European footprint and growth/buyout orientation.
  • Bridgepoint: European mid-market private equity firm focused on profitable growth companies; similar ticket size range, pan-European deal sourcing and growth-buyout model make Bridgepoint a direct comparable.
  • PAI Partners: Paris-based European private equity firm with growth-buyout focus across multiple sectors; comparable ticket sizes, French/European headquarters and mid-market growth orientation align closely with Keensight's positioning.
  • Hg: London-based private equity firm exclusively focused on European software and technology-enabled services; similar sector specialization, mid-market ticket sizes and value-creation orientation make Hg the closest pure-technology comparable to Keensight's tech portfolio.
  • Astorg: Paris-headquartered European private equity firm focused on mid-market buyouts in technology, healthcare and business services; closely comparable in French origin, sector focus and growth-buyout approach.

Broad incumbents

  • CVC Capital Partners: Global private equity firm and existing Keensight co-investor (Sogelink); larger AUM and broader sector mandate make it an incumbent comparable rather than a direct peer, but the partnership dynamic is material to Keensight's deal flow.
  • EQT Partners: Global private equity firm with strong European technology and healthcare franchises (EQT Growth, EQT Healthcare); much larger scale and broader strategy, but directly comparable in sector focus and European mid-large growth-buyout activity.
  • BC Partners: European-headquartered global private equity firm executing mid-to-large buyouts; overlapping European deal flow and growth-buyout orientation, though at a larger average ticket size than Keensight.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Keensight Capital social profiles

Digital presence

Keensight Capital compliance and trust

Trust signal

Compliance5 records

Keensight Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Keensight Capital leadership team

Management profile

Number of profiles

Profiles22 records

Keensight Capital subsidiaries and ownership

Company hierarchy

Subsidiaries34 records

Keensight Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Keensight Capital M&A and investment

M&A and investment

M&A28 records

Investments31 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Keensight Capital

What does Keensight Capital do?

Keensight Capital is a European Growth Buyout investor that deploys €10–800m tickets in minority or majority positions into profitable, fast-growing European Technology and Healthcare companies generating €10–400m in revenues. The firm provides capital alongside strategic guidance and operational support delivered through its proprietary Keensight Performance team of ~40 in-house professionals, while Keensight Connect serves as the online community platform for portfolio company executives.

Is Keensight Capital a public or private company?

Keensight Capital is a private company. It is classified as management employee owned and is currently operating.

When was Keensight Capital founded?

Keensight Capital was founded in 2000. It employs 101 to 250 people.

Where is Keensight Capital based?

Keensight Capital is headquartered in London, United Kingdom, in the Europe region.

How does Keensight Capital make money?

Two revenue lines are on record. Private equity fund management fees & carried interest is the primary driver. The others are fund capital deployment gains.

Who are Keensight Capital's main competitors?

Direct peers on record are Ardian, Eurazeo, Tikehau Capital, Bridgepoint, PAI Partners, Hg and Astorg. Broad incumbents are CVC Capital Partners, EQT Partners and BC Partners.

Does Keensight Capital have an API?

No public API is recorded for Keensight Capital.

What industry is Keensight Capital in?

Keensight Capital's product category is Private Equity / Growth Buyout Investing. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingKeensight Capital appoints Eduardo Ariño de la Rubia as managing director and head of AIKeensight Capital appointed Eduardo Ariño de la Rubia as managing director and head of AI, a newly created role. He will coordinate and scale AI initiatives across the firm and portfolio companies, building on work started in 2018. Ariño de la Rubia spent eight years at Meta as senior director of data science, with over 25 years of AI experience.Lincoln International LLCKeensight Capital has entered into an agreement for the acquisition of Smile – the European leader in digital and open sourceKeensight Capital entered exclusive negotiations to acquire a majority stake in Smile, a European digital and open-source firm. Smile, with 1,700 employees and €130m revenue in 2019, will benefit from Keensight's network and Eurazeo PME's advisory. The deal aims to support Smile's Open Arrow 2.0 plan for international expansion and advisory growth.Worcester Business JournalHopkinton’s Isto Biologics acquires Florida bonehealing firm for $60MIsto Biologics acquired Florida-based NovaBone Products from Halma for $60 million. The purchase expands Isto's bone graft substitute offerings, which are used in over 15,000 U.S. surgical procedures monthly. NovaBone, founded in 2022, develops synthetic bone graft materials.openPR.comFuture Perspectives: Key Trends Shaping the Physical Security Information Management (PSIM) Market Until 2030The Physical Security Information Management (PSIM) market is projected to reach $4.17 billion by 2030, growing at a compound annual growth rate of 16.4%, driven by smart city initiatives, cloud-based security platforms, and modernized public safety infrastructure. In November 2024, Advancis Software & Services GmbH, a German provider of integrated physical security software, entered into a strategic partnership with French private equity firm Keensight Capital to accelerate its international growth and PSIM solution development. In March 2023, Advancis launched two new products: WinGuard X5 and Advanced Identity Manager (AIM), targeting improved operational workflows and secure identity management.Biz BahrainPerfect Corp. Enhances Keensight’s 3D Medical Beauty Consulting Experience through Powerful AI Skin Analysis APIsPerfect Corp. partnered with Keensight to integrate its AI skin analysis APIs into the Lummitry 3D medical beauty consulting platform. The integration raised average consultation conversion rates by over 50% and shortened decision times. Both companies plan to add more AI features to set a new global standard in medical and beauty tech.Business Wire BlogPerfect Corp. Enhances Keensight’s 3D Medical Beauty Consulting Experience through Powerful AI Skin Analysis APIsPerfect Corp. integrated its AI skin analysis APIs into Keensight's Lummitry 3D medical beauty consulting platform. The integration boosted consultation conversion rates by over 50% and shortened decision times. Both companies plan to add more AI features to set a new global standard.Empresas de Capital Riesgo en EspaInke, backed by Keensight Capital, acquires Pharmanoid, a Highly Potent API manufacturing site specializing in ophthalmologyInke, a global manufacturer of inhalation APIs and HPAPIs backed by private equity firm Keensight Capital, has acquired Pharmanoid from Gentec Pharmaceutical Group. Pharmanoid is a Spain-based manufacturing site specializing in the production of HPAPIs for ophthalmology, including prostaglandins used as first-line treatment for glaucoma. The acquisition broadens Inke's portfolio beyond respiratory APIs, enhances its HPAPI capabilities, and advances its ambition to build a European leader in advanced API development and manufacturing.Empresas de Capital Riesgo en EspaCuatrecasas advises UVE Solutions on the sale of a majority stake to Keensight to accelerate its expansionCuatrecasas advised the Catalan company UVE Solutions on the sale of a majority stake to Paris-based Keensight, a private equity firm specializing in growth investments for companies with revenues up to €400 million. The transaction will accelerate UVE Solutions' international and vertical expansion in the FMCG sector while enabling new investments in artificial intelligence-based innovation across its product portfolio. UVE Solutions, founded in 2007 in Manresa (Barcelona), specializes in data-intelligence solutions for fast-moving consumer goods and fragmented distribution channels.Pulse 2.0Keensight Capital Expands Leadership Team With Senior Human Resources AppointmentsKeensight Capital appointed Berengere Peter as Partner and Head of Human Resources and added Halina Evans as HR Director in London. The firm, managing €6 billion in assets, has more than doubled its team to over 125 professionals. The appointments support its next phase of global expansion.Mugglehead MagazineKeensight Capital takes majority stake in breath analysis device makerKeensight Capital, a European venture capital firm, has acquired a majority stake in Bedfont Scientific, a breath analysis technology company established in 1976 that makes devices for diagnosing asthma, detecting gastrointestinal disorders, and supporting smoking cessation. The deal value and exact percentage were not disclosed. The investment aligns with Keensight's focus on medtech companies that impact patient care, and Bedfont will continue operating under its existing leadership while aiming to expand globally into new markets.